Physician profile
Stephen L Morris
NPI 1538104567
$4,608.39
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $784 · 2021: $1,682 · 2022: $115 · 2023: $51.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $655.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $619.12 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.20 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $314.87 | 2019-2022 | |
| Grifols USA, LLC | $264.93 | 2019-2022 | |
| Philips North America LLC | $263.36 | 2019-2021 | |
| Insmed, INC. | $253.91 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $237.78 | 2019-2021 | |
| Genzyme Corporation | $153.64 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $130.08 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $81.34 | 2019-2021 | |
| United Therapeutics Corporation | $80.58 | 2021 | |
| Allergan, INC. | $73.77 | 2019-2020 | |
| Genentech USA, INC. | $68.01 | 2019 | |
| Mylan Specialty L.P. | $63.82 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $63.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $59.41 | 2019-2021 | |
| Harmony Biosciences LLC | $57.14 | 2020-2021 | |
| Shire North American Group INC | $51.06 | 2019 | |
| Sunovion Pharmaceuticals INC. | $50.97 | 2019 | |
| Circassia INC. | $50.36 | 2019 | |
| Mallinckrodt Enterprises LLC | $48.45 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $45.63 | 2019 | |
| Advanced Respiratory, INC | $39.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.04 | 2019 | |
| Axsome Therapeutics, INC. | $28.82 | 2023 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $24.14 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.13 | 2021 | |
| Adma Biomanufacturing LLC | $23.09 | 2021 | |
| Pharming Healthcare, INC. | $22.65 | 2023 | Ruconest |
| Phadia US INC. | $17.46 | 2021 | |
| Abbvie INC. | $17.19 | 2021 | |
| Biogen, INC. | $16.00 | 2021 | |
| Fisher & Paykel Healthcare INC | $14.95 | 2019 | |
| Csl Behring | $14.64 | 2020 | |
| Apria Healthcare LLC | $14.18 | 2021 | |
| Electromed, INC. | $13.91 | 2021 | |
| Smith+Nephew, INC. | $11.00 | 2019 | |
| Ambu INC. | $5.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.